Management of neovascular glaucoma with transscleral cyclophotocoagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser and intravitreal bevacizumab

Fong, Anthony W., Lee, Graham A., O'Rourke, Peter and Thomas, Ravi (2011) Management of neovascular glaucoma with transscleral cyclophotocoagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser and intravitreal bevacizumab. Clinical And Experimental Ophthalmology, 39 4: 318-323. doi:10.1111/j.1442-9071.2010.02449.x


Author Fong, Anthony W.
Lee, Graham A.
O'Rourke, Peter
Thomas, Ravi
Title Management of neovascular glaucoma with transscleral cyclophotocoagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser and intravitreal bevacizumab
Journal name Clinical And Experimental Ophthalmology   Check publisher's open access policy
ISSN 1442-6404
1442-9071
Publication date 2011-05-01
Year available 2010
Sub-type Article (original research)
DOI 10.1111/j.1442-9071.2010.02449.x
Volume 39
Issue 4
Start page 318
End page 323
Total pages 6
Place of publication Richmond, VIC, Australia
Publisher Wiley-Blackwell Publishing Asia
Language eng
Formatted abstract
Background:
Trans-scleral cyclophotocoagulation with diode laser has been well documented in the management of neovascular glaucoma. More recently, intravitreal bevacizumab has been increasingly employed to treat neovascular diseases of the eye. This study reports our initial experience with trans-scleral cyclophotocoagulation alone versus the combination of trans-scleral cyclophotocoagulation and intravitreal bevacizumab for management of neovascular glaucoma.

Design:

Retrospective uncontrolled comparative case series

Participants:
A total of 31 eyes of 30 consecutive patients were included – 11 eyes in the trans-scleral
cyclophotocoagulation alone group and 20 in the combination trans-scleral cyclophotocoagulation and intravitreal bevacizumab group.

Methods:
The records of all patients diagnosed with neovascular glaucoma undergoing trans-scleral cyclophotocoagulation with or without intravitreal bevacizumab performed by a single ophthalmic surgeon in a glaucoma specialist centre were reviewed.

Main Outcome Measures:

Data collected included intraocular pressure, anterior segment neovascularisation,
best-corrected visual acuity, use of medications and complications.

Results:

Mean reduction in intraocular pressure was 33.5 mmHg in the trans-scleral cyclophotocoagulation group and 23.7 mmHg in the combination
group, a difference of 9.8 mmHg (95% CI -1.5, 21.1). Complications included hypotony in three (27%) eyes in the trans-scleral cyclophotocoagulation group and two (10%) eyes in the combination group. Three eyes required evisceration.

Conclusions:

Trans-scleral cyclophotocoagulation alone is effective in lowering intraocular pressure in
neovascular glaucoma. In this study, the addition of intravitreal bevacizumab to trans-scleral cyclophotocoagulation did not statistically advantage treatment outcomes.
Keyword Bevacizumab
Cyclodiode
Cyclophotocoagulation
Diode laser
Neovascular glaucoma
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article first published online: 23 DEC 2010 Early View (Online Version of Record published before inclusion in an issue) This work has been presented in part at the Royal Australian and New Zealand Annual Scientific Congress of Ophthalmology, 2009, Brisbane, Australia.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2011 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 15 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 19 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 28 Mar 2011, 19:09:37 EST by Debbie Banks on behalf of School of Medicine